definiens: means : 1 . the discovery, isolation, characterization, research, development, and/or commercialization of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following disease conditions wherein the primary scientific L rationale or activity is lleuronal and/or glial mechanisms of action or neuroprotection ; 2.neurodegenerative conditions including, without limitation, ( A ) Alzheimer 's disease, and ( BH ~ arkinson 's diseaseibut, in both instances, excluding the treatment and/or prevention of tieurodegenerative conditions in humans associated withj}-:amyloid deposition ( including, without limitation, Alzheimer 's disease and/or Mild Cognitive Impairment u ~ ing either ( 1 ) immunological approaches directed at one or more epitopes of Aj ), or any naturally occurring variants thereof ( including, without limitation, the administration of an Antibody ), or ( 2 ) use of a beta secretase inhibitor ( including, without limitation, the administration of an Antibody » ) ; 3 . diabetic neuropathy~ 4 . pain, including, but not limited to, ( A ) post - operative pain, ( B ) chronic pain ) and ( C ) neuropathic pain ; 5 . spinal cord injury ; 6 . multiple sclerosis ; and/or 7 . stroke, as a disease of the cerebrovasculature ; provided, however, that for the purpose of this Agreement the term will not include the diagnosis, treatment an~~revention of the above disease conditions caused by infectious pathogenic micrO - OrganiS~ SCHEDULE V Excluded Technologies means : 1 . ( meaning the technology claimed in the following Patents ; to which CAT has sole right, title and interest : ( a ) Cell ~ free synthesis and isolation of · novel genes and polypeptides PCT / US90/05682, filed 2 October 1990 ; ( b ) Improvements to Ribosome Display, PCT / GBOl/01319 filed March 26, 2001 ; 2 . meaning solely Antibodies which .bind to and catalyze the chemical transformation of a substrate and in which an Antibody binding region is involved in said catalysis ; 3 . meaning those certain research products for which CAT has granted certain exclusive rights to a Third Party under the Amersham License Agreement, as may then be in effect ; 4 . " Microarrays : ' meaning any Antibody microarrayproduct for the purpose of simultaneously detecting and/or measuring Antigens whereby that product : ( a ) Contains or comprises : ( i ) anarrayofthree ( 3.);or more Antibodies of different Antigen specificity ( excluding Antibodies serving a purpose as controls ), or ( ii ) anaqay of one ( l):qrmoreAntibodies of the same Antigen $ pecificity, provided that such Antibody is used to { ietect and/or i):1easure three ( 3 ) or more data points for the purpose of quantifying the Antigen ( excluding Antibodies serving a purpose as controls ), and ( b ) contains or comprises an array of Antibodies affixed to a supporting surface either before or after binding to Antigen, and ( c ) is in a format where the ~ntibodies are combined with one test sample of multiple Antigens, and ( d ) employs any type ofmicrofluidics ~ based : screening system, and ( e ) may be used t12 vitro or invivO'(as appropriate ), and ( f ) is not, by way of example, ( i ) any type ofimmunochemical ELISA or EIA technology ; ( ii ) any type of RIA technology ; ( iii ) any type of immunochromatographicassay ~ SCHEDULE VI CA T Third Party Claims fMOfJ > hOSYS v. CAT ( re McCafferty ) -Washington D. C. District Court 2 . Morphosys v. CAT ( re Griffiths ) -Washington D.C District Court 3 . Morphosys v. CAT ( re Winter II ) -Washington D.C District Court 4 . Morphosys v. CAT ( re Winter / Ruse / Lerner ) -Washington D.C District Court 5 . CAT v. Morphosys ( re McCafferty and Winter ) -Munich District Court 6 . George Pieczenik v. James W. Fordyce, et al . ( Civil Action 03 CV 6336 ) -Southern District I of New York District Court ~ T ABLE OF CONTENTS I)AGE 1 . DEFINITIONS ............................................................................................................... 1 2 . GRANT OF LICENSES ................................................................................................. 7 2.1 License ............................................................................................................... 7 2.2 Reservation of Rights .......................................................................................... 7 2.3 Excluded Technology ......................................................................................... 7 2.4 Know - How Transfer ........................................................................................... 8 3 . IDENTIFICATION OF LICENSED PRODUCTS ; REPORTING ; DILIGENCE ........... 8 3.1 Identification of Licensed Products ..................................................................... 8 3.2 Abandonment ofa Licensed Product .. ................................................................. 8 3.3 Dossier Updates .................................................................................................. 9 4 . GATEKEEPING AND THE EXCLUDED FIELD ......................................................... 9 5 . PAyMENTS .................................................................................................................. 9 5.1 Initial License Fee ............................................................................................... 9 5.2 Therapeutic Licensed Product Milestone Payments and Royalty Rates ................ 9 5.3 Diagnostic Lieensed Product Milestone Payments and Royalty Rates ............... 10 5.4 Payment . ........................................................................................................... 11 5.5 Records ; Audits ................................................................................................ 12 5.6 Payment of Additional Amounts ....................................................................... 13 5.7 Confidentiality .................................................................................................. 13 5.8 Withholdings .................................................................................................... 13 6 . REPRESENTATION AND WARRANTIES ; COVENANTS ...................................... 14 6.1 Representations of CAT .................................................................................... 14 6.2 Reciprocal Representations and Warranties ....................................................... 14 6.3 Additional Covenants ........................................................................................ 15 6.4 DISCLAIMER OF WARRANTy ..................................................................... 15 7 . CONFIDENTIALITY .................................................................................................. 15 7.1 Definition ......................................................................................................... 15 7.2 Exclusions ........................................................................................................ 15 7.3 Disclosure and Use Restriction ......................................................................... 16 7.4 Authorized Disclosure ...................................................................................... 16 -1 - 11 T ABLE OF CONTENTS ( CONTINUED ) PAGE 7.5 Use of Name ..................................................................................................... 17 7.6 Tenns of Agreement to be Maintained in Confidence ....................................... 17 7.7 Press Release .................................................................................................... 17 8 . FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS ................. 18 8.1 Prosecution and Maintenance ............................................................................ 18 8.2 Costs ................................................................................................................. 18 8.3 No Challenge .................................................................................................... 18 8.4 Notice ............................................................................................................... 18 8.5 Enforcement ..................................................................................................... 18 9 . IMPROVEMENTS ; OWNERSHIP .............................................................................. IS 9.1 Phage Display Improvements ............................................................................ lS 9.2 CAT Phage Display Improvements ................................................................... 19 9.3 Further Assurances ........................................................................................... 19 10 . TERM AND TERMINATION ..................................................................................... 19 ] 0.1 Tenn ................................................................................................................. 19 10.2 Termination for Material Breach ....................................................................... 20 10.3 Amendment or Tennination of'MRCAgreement .............................................. 20 10.4 Consequences of Expiration and Tennination ................................................... 20 10.5 Survival ............................................................................................................ 21 11 . INDEMNIFICATION AND INSURANCE .................................................................. 21 1].1 Indemnification By Licensee ............................................................................. 21 11.2 Indemnification Procedure ................................................................................ 22 11.3 Expenses ........................................................................................................... 23 11.4 Insurance .......................................................................................................... 23 12 . LIMITATION OF LIABILITY .................................................................................... 23 13 . MISCELLANEOUS ..................................................................................................... 24 13.1 Assignment ....................................................................................................... 24 13.2 Severability ....................................................................................................... 25 13.3 Governing Law ; Dispute Resolution ................................................................. 25 13.4 Notices ............................................................................................................. 25 -ll - T ABLE OF CONTENTS ( CONTINUED ) PAGE ] 3.5 Entire Agreement ; Modifications ...................................................................... 26 13.6 Relationship of the Parties ................................................................................ 26 13.7 Waiver .............................................................................................................. 27 13.8 Counterparts ..................................................................................................... 27 13.9 No Benefit to Third Parties ............................................................................... 27 13.10 Further Assurance ............................................................................................. 27 13.11 English Language ............................................................................................. 27 13.12 Force Majeure ................................................................................................. 27 13.13 Construction ..................................................................................................... 27 151698 v20 / RE 391%20!.DOC -iii - AMENDMENT TO NON - EXCLUSIVE PRODUCT LICENSE AGREEMENT THIS AMENDMENT ( the ) is made as of this 17th day of March, 2005 by and between MICROMET AG, located at Staffelseestrasse 2, D-8l477, Munich, Germany ( ) and Cambridge Antibody Technology Limited, located at The Milstein Building, Granta Park, Cambridgeshire CB 1 6GH, England ( PartyParties " )